[10-Q] Ensysce Biosciences, Inc. Quarterly Earnings Report
Ensysce Biosciences is a clinical-stage biotech focused on TAAP and MPAR technologies; PF614 is in Phase 3 and PF614-MPAR is in Phase 1b. The company reported $2.21 million in cash at June 30, 2025 (from $3.50M), total assets of $5.57 million and total liabilities of $2.51 million. For the six months ended June 30, 2025 the net loss was $3.68 million versus $5.08M a year earlier; federal grant revenue was $2.69 million year-to-date and remaining NIH MPAR grant funding was disclosed as $9.4 million as of June 30, 2025. Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern and states current cash is sufficient into the third quarter of 2025. Recent financing actions generated gross proceeds of approximately $2.2M from an April 2025 warrant inducement and approximately $1.1M from a March 2025 registered direct offering, with an additional $1.1M raised from warrant exercises after June 30, 2025. The company carries ~3.42M warrants outstanding and has open purchase commitments of about $8.3M.
Ensysce Biosciences 猫 una biotech in fase clinica focalizzata sulle tecnologie TAAP e MPAR; PF614 猫 in Fase 3 e PF614-MPAR 猫 in Fase 1b. La societ脿 ha riportato $2.21 million in cash al 30 giugno 2025 (da $3.50M), attivit脿 totali di $5.57 million e passivit脿 totali di $2.51 million. Per i sei mesi chiusi il 30 giugno 2025 la perdita netta 猫 stata di $3.68 million rispetto a $5.08M dell'anno precedente; i ricavi da sovvenzioni federali sono stati di $2.69 million da inizio anno e il finanziamento residuo del grant NIH MPAR 猫 stato indicato in $9.4 million al 30 giugno 2025. La direzione dichiara notevoli dubbi sulla capacit脿 dell鈥檃zienda di proseguire come azienda in funzionamento e afferma che la cassa attuale 猫 sufficiente fino al terzo trimestre del 2025. Operazioni finanziarie recenti hanno generato proventi lordi di circa $2.2M da un incentivo all'esercizio di warrant ad aprile 2025 e circa $1.1M da un'offerta diretta registrata a marzo 2025, con un ulteriore $1.1M raccolto dall'esercizio di warrant dopo il 30 giugno 2025. La societ脿 ha in circolazione circa 3.42M warrant e impegni di acquisto aperti per circa $8.3M.
Ensysce Biosciences es una empresa biotecnol贸gica en fase cl铆nica centrada en las tecnolog铆as TAAP y MPAR; PF614 est谩 en Fase 3 y PF614-MPAR en Fase 1b. La compa帽铆a inform贸 $2.21 million in cash al 30 de junio de 2025 (desde $3.50M), activos totales de $5.57 million y pasivos totales de $2.51 million. Para los seis meses terminados el 30 de junio de 2025 la p茅rdida neta fue de $3.68 million frente a $5.08M un a帽o antes; los ingresos por subvenciones federales ascendieron a $2.69 million en lo que va del a帽o y el financiamiento restante de la subvenci贸n NIH MPAR se declar贸 en $9.4 million al 30 de junio de 2025. La direcci贸n revela dudas sustanciales sobre la capacidad de la compa帽铆a para continuar como negocio en marcha y afirma que la liquidez actual es suficiente hasta el tercer trimestre de 2025. Acciones de financiaci贸n recientes generaron ingresos brutos de aproximadamente $2.2M por una inducci贸n de warrants en abril de 2025 y aproximadamente $1.1M por una colocaci贸n directa registrada en marzo de 2025, con un adicional de $1.1M recaudado por ejercicios de warrants despu茅s del 30 de junio de 2025. La compa帽铆a mantiene alrededor de 3.42M warrants pendientes y tiene compromisos de compra abiertos por aproximadamente $8.3M.
Ensysce Biosciences電� TAAP 氚� MPAR 旮办垹鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤鞛呺媹雼�; PF614電� 3靸�, PF614-MPAR電� 1b靸侅棎 鞛堨姷雼堧嫟. 須岇偓電� 2025雲� 6鞗� 30鞚� 旮办 $2.21 million in cash鞚� 氤搓碃頄堨溂氅�(旮办〈 $3.50M鞐愳劀), 齑濎瀽靷办潃 $5.57 million, 齑濍秬毂勲姅 $2.51 million鞓�鞀惦媹雼�. 2025雲� 6鞗� 30鞚茧 雭濍倶電� 6臧滌洈 霃欖晥 靾滌啇鞁れ潃 $3.68 million鞙茧 鞝勲厔 霃欔赴 $5.08M鞐愳劀 臧滌劆霅橃棃瓿�, 鞐半癌 氤挫“旮� 靾橃澋鞚� 鞐办磮 雽�牍� $2.69 million鞚挫棃鞙茧┌ NIH MPAR 氤挫“旮堨潣 鞛旍棳 鞛愱笀鞚� 2025雲� 6鞗� 30鞚� 旮办 $9.4 million鞙茧 瓿奠嫓霅橃棃鞀惦媹雼�. 瓴届榿歆勳潃 須岇偓臧� 瓿勳啀旮办梾鞙茧 臁挫啀頃� 靾� 鞛堧姅歆�鞐� 雽�頃� 欷戨寑頃� 鞚橂(靸侂嫻頃� 攵堩檿鞁れ劚)鞚� 鞛堧嫟瓿� 瓿店皽頄堨溂氅� 順勳灛 順勱笀鞚� 2025雲� 3攵勱赴旯岇 於╇秳頃橂嫟瓿� 氚濏様鞀惦媹雼�. 斓滉芳 鞛愱笀 臁半嫭搿� 2025雲� 4鞗� 鞗岆煱韸� 鞙犽弰鞐愳劀 鞎� $2.2M鞚� 齑濎垬鞚奠潉, 2025雲� 3鞗� 霌彪 歆侅爲瓿惦鞐愳劀 鞎� $1.1M鞚� 頇曤炒頄堨溂氅� 2025雲� 6鞗� 30鞚� 鞚错泟 鞗岆煱韸� 頄夓偓搿� 於旉皜 $1.1M鞚� 臁半嫭頄堨姷雼堧嫟. 須岇偓電� 鞎� 3.42M臧滌潣 鞗岆煱韸戈皜 鞙犿喌 欷�鞚措┌ 鞎� $8.3M鞚� 氙戈舶 毵れ垬 鞎届爼鞚� 鞛堨姷雼堧嫟.
Ensysce Biosciences est une biotech en phase clinique ax茅e sur les technologies TAAP et MPAR ; PF614 est en phase 3 et PF614-MPAR en phase 1b. La soci茅t茅 a d茅clar茅 $2.21 million in cash au 30 juin 2025 (contre $3.50M), des actifs totaux de $5.57 million et des passifs totaux de $2.51 million. Pour les six mois clos le 30 juin 2025, la perte nette s'est 茅lev茅e 脿 $3.68 million contre $5.08M un an plus t么t ; les revenus des subventions f茅d茅rales s'茅l猫vent 脿 $2.69 million depuis le d茅but de l'ann茅e et le financement restant de la subvention NIH MPAR a 茅t茅 indiqu茅 脿 $9.4 million au 30 juin 2025. La direction fait 茅tat de doutes importants quant 脿 la capacit茅 de la soci茅t茅 脿 poursuivre son activit茅 et indique que la tr茅sorerie actuelle est suffisante jusqu'au troisi猫me trimestre 2025. Des op茅rations de financement r茅centes ont g茅n茅r茅 des produits bruts d'environ $2.2M suite 脿 une induction de warrants en avril 2025 et d'environ $1.1M lors d'une offre directe enregistr茅e en mars 2025, avec un suppl茅ment de $1.1M lev茅 gr芒ce 脿 l'exercice de warrants apr猫s le 30 juin 2025. La soci茅t茅 dispose d'environ 3.42M de warrants en circulation et a des engagements d'achat ouverts d'environ $8.3M.
Ensysce Biosciences ist ein Biotech-Unternehmen in der klinischen Entwicklungsphase, das sich auf TAAP- und MPAR-Technologien konzentriert; PF614 befindet sich in Phase 3 und PF614-MPAR in Phase 1b. Das Unternehmen meldete am 30. Juni 2025 $2.21 million in cash (von $3.50M), Gesamtverm枚gen von $5.57 million und Gesamtverbindlichkeiten von $2.51 million. F眉r die sechs Monate zum 30. Juni 2025 betrug der Nettoverlust $3.68 million gegen眉ber $5.08M im Vorjahr; die Einnahmen aus Bundeszusch眉ssen beliefen sich bisher auf $2.69 million und die verbleibende NIH-MPAR-Zuschussfinanzierung wurde zum 30. Juni 2025 mit $9.4 million angegeben. Das Management weist erhebliche Zweifel an der F盲higkeit des Unternehmens aus, als fortf眉hrendes Unternehmen fortzubestehen und erkl盲rt, dass die derzeitigen Barmittel bis ins dritte Quartal 2025 ausreichen. K眉rzliche Finanzierungsma脽nahmen erzielten Bruttoerl枚se von etwa $2.2M durch eine Warrant-Induzierung im April 2025 und etwa $1.1M durch ein im M盲rz 2025 registriertes Direktangebot, wobei zus盲tzlich $1.1M aus Warrant-Aus眉bungen nach dem 30. Juni 2025 eingeworben wurden. Das Unternehmen h盲lt etwa 3.42M ausstehende Warrants und hat offene Kaufverpflichtungen von rund $8.3M.
- Federal grant funding: $2.69M recognized for the six months ended June 30, 2025 and $9.4M remaining under the MPAR grant as of June 30, 2025.
- Recent financings: April 2025 warrant inducement raised ~$2.2M gross and March 2025 registered direct offering raised ~$1.1M gross, plus ~$1.1M of warrant exercise proceeds after June 30, 2025.
- Clinical progress: Lead candidate PF614 in Phase 3; PF614-MPAR in Phase 1b; nafamostat completed Phase 1.
- Grant-supported revenue recognition policy: Company recognizes reimbursable grant revenue as related costs are incurred, providing a predictable near-term funding source tied to R&D activity.
- Going concern: Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern and states cash suffices only into the third quarter of 2025.
- Liquidity erosion: Cash decreased to $2.21M at June 30, 2025 from $3.50M at December 31, 2024 while the six-month net loss was $3.68M.
- Large accumulated deficit: Accumulated deficit of $133.22M reduces flexibility and reflects sustained historical losses.
- Potential dilution: Approximately 3.42M warrants outstanding and ~3.55M total shares reserved for future issuance, creating significant dilution risk.
- Commitments and vendor concentration: Open purchase commitments of ~$8.3M and concentration of accounts payable (one or three R&D vendors >10% individually; 55% and 74% in aggregate) could strain cash and supplier relationships.
Insights
Pre-revenue biotech with limited cash, material net losses and substantial doubt about going concern despite recent financings.
Ensysce remains pre-revenue and dependent on grant funding and capital markets. Cash fell to $2.21M at June 30, 2025 while the six-month net loss was $3.68M, and management states cash is sufficient only into the third quarter of 2025, creating clear liquidity pressure. Federal grant receipts ($2.69M year-to-date and $9.4M remaining MPAR grant funding) and recent equity/warrant financings (~$3.3M gross across March and April transactions) provide short-term relief but do not eliminate going-concern risk. The company鈥檚 $8.3M of open purchase commitments and large outstanding warrant pool amplify the potential need for additional financing or dilution.
Frequent warrant inducements and successive financings have produced dilution and significant equity issuance costs.
Ensysce has executed multiple inducements and registered offerings (notably February 2024, August 2024, March 2025 and April 2025) that raised cash but also produced large equity issuance costs (the company recognized effects of warrant modifications of approximately $10.2M and $5.2M in prior transactions) and expanded the outstanding warrant count to about 3.42M. The capital structure now includes various warrant series with staggered expirations and significant potential dilution relative to shares outstanding. A related-party promissory note to a board member is in forbearance through April 25, 2026, which is a governance item investors should note. These factors materially affect shareholder economics and strategic flexibility.
Ensysce Biosciences 猫 una biotech in fase clinica focalizzata sulle tecnologie TAAP e MPAR; PF614 猫 in Fase 3 e PF614-MPAR 猫 in Fase 1b. La societ脿 ha riportato $2.21 million in cash al 30 giugno 2025 (da $3.50M), attivit脿 totali di $5.57 million e passivit脿 totali di $2.51 million. Per i sei mesi chiusi il 30 giugno 2025 la perdita netta 猫 stata di $3.68 million rispetto a $5.08M dell'anno precedente; i ricavi da sovvenzioni federali sono stati di $2.69 million da inizio anno e il finanziamento residuo del grant NIH MPAR 猫 stato indicato in $9.4 million al 30 giugno 2025. La direzione dichiara notevoli dubbi sulla capacit脿 dell鈥檃zienda di proseguire come azienda in funzionamento e afferma che la cassa attuale 猫 sufficiente fino al terzo trimestre del 2025. Operazioni finanziarie recenti hanno generato proventi lordi di circa $2.2M da un incentivo all'esercizio di warrant ad aprile 2025 e circa $1.1M da un'offerta diretta registrata a marzo 2025, con un ulteriore $1.1M raccolto dall'esercizio di warrant dopo il 30 giugno 2025. La societ脿 ha in circolazione circa 3.42M warrant e impegni di acquisto aperti per circa $8.3M.
Ensysce Biosciences es una empresa biotecnol贸gica en fase cl铆nica centrada en las tecnolog铆as TAAP y MPAR; PF614 est谩 en Fase 3 y PF614-MPAR en Fase 1b. La compa帽铆a inform贸 $2.21 million in cash al 30 de junio de 2025 (desde $3.50M), activos totales de $5.57 million y pasivos totales de $2.51 million. Para los seis meses terminados el 30 de junio de 2025 la p茅rdida neta fue de $3.68 million frente a $5.08M un a帽o antes; los ingresos por subvenciones federales ascendieron a $2.69 million en lo que va del a帽o y el financiamiento restante de la subvenci贸n NIH MPAR se declar贸 en $9.4 million al 30 de junio de 2025. La direcci贸n revela dudas sustanciales sobre la capacidad de la compa帽铆a para continuar como negocio en marcha y afirma que la liquidez actual es suficiente hasta el tercer trimestre de 2025. Acciones de financiaci贸n recientes generaron ingresos brutos de aproximadamente $2.2M por una inducci贸n de warrants en abril de 2025 y aproximadamente $1.1M por una colocaci贸n directa registrada en marzo de 2025, con un adicional de $1.1M recaudado por ejercicios de warrants despu茅s del 30 de junio de 2025. La compa帽铆a mantiene alrededor de 3.42M warrants pendientes y tiene compromisos de compra abiertos por aproximadamente $8.3M.
Ensysce Biosciences電� TAAP 氚� MPAR 旮办垹鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤鞛呺媹雼�; PF614電� 3靸�, PF614-MPAR電� 1b靸侅棎 鞛堨姷雼堧嫟. 須岇偓電� 2025雲� 6鞗� 30鞚� 旮办 $2.21 million in cash鞚� 氤搓碃頄堨溂氅�(旮办〈 $3.50M鞐愳劀), 齑濎瀽靷办潃 $5.57 million, 齑濍秬毂勲姅 $2.51 million鞓�鞀惦媹雼�. 2025雲� 6鞗� 30鞚茧 雭濍倶電� 6臧滌洈 霃欖晥 靾滌啇鞁れ潃 $3.68 million鞙茧 鞝勲厔 霃欔赴 $5.08M鞐愳劀 臧滌劆霅橃棃瓿�, 鞐半癌 氤挫“旮� 靾橃澋鞚� 鞐办磮 雽�牍� $2.69 million鞚挫棃鞙茧┌ NIH MPAR 氤挫“旮堨潣 鞛旍棳 鞛愱笀鞚� 2025雲� 6鞗� 30鞚� 旮办 $9.4 million鞙茧 瓿奠嫓霅橃棃鞀惦媹雼�. 瓴届榿歆勳潃 須岇偓臧� 瓿勳啀旮办梾鞙茧 臁挫啀頃� 靾� 鞛堧姅歆�鞐� 雽�頃� 欷戨寑頃� 鞚橂(靸侂嫻頃� 攵堩檿鞁れ劚)鞚� 鞛堧嫟瓿� 瓿店皽頄堨溂氅� 順勳灛 順勱笀鞚� 2025雲� 3攵勱赴旯岇 於╇秳頃橂嫟瓿� 氚濏様鞀惦媹雼�. 斓滉芳 鞛愱笀 臁半嫭搿� 2025雲� 4鞗� 鞗岆煱韸� 鞙犽弰鞐愳劀 鞎� $2.2M鞚� 齑濎垬鞚奠潉, 2025雲� 3鞗� 霌彪 歆侅爲瓿惦鞐愳劀 鞎� $1.1M鞚� 頇曤炒頄堨溂氅� 2025雲� 6鞗� 30鞚� 鞚错泟 鞗岆煱韸� 頄夓偓搿� 於旉皜 $1.1M鞚� 臁半嫭頄堨姷雼堧嫟. 須岇偓電� 鞎� 3.42M臧滌潣 鞗岆煱韸戈皜 鞙犿喌 欷�鞚措┌ 鞎� $8.3M鞚� 氙戈舶 毵れ垬 鞎届爼鞚� 鞛堨姷雼堧嫟.
Ensysce Biosciences est une biotech en phase clinique ax茅e sur les technologies TAAP et MPAR ; PF614 est en phase 3 et PF614-MPAR en phase 1b. La soci茅t茅 a d茅clar茅 $2.21 million in cash au 30 juin 2025 (contre $3.50M), des actifs totaux de $5.57 million et des passifs totaux de $2.51 million. Pour les six mois clos le 30 juin 2025, la perte nette s'est 茅lev茅e 脿 $3.68 million contre $5.08M un an plus t么t ; les revenus des subventions f茅d茅rales s'茅l猫vent 脿 $2.69 million depuis le d茅but de l'ann茅e et le financement restant de la subvention NIH MPAR a 茅t茅 indiqu茅 脿 $9.4 million au 30 juin 2025. La direction fait 茅tat de doutes importants quant 脿 la capacit茅 de la soci茅t茅 脿 poursuivre son activit茅 et indique que la tr茅sorerie actuelle est suffisante jusqu'au troisi猫me trimestre 2025. Des op茅rations de financement r茅centes ont g茅n茅r茅 des produits bruts d'environ $2.2M suite 脿 une induction de warrants en avril 2025 et d'environ $1.1M lors d'une offre directe enregistr茅e en mars 2025, avec un suppl茅ment de $1.1M lev茅 gr芒ce 脿 l'exercice de warrants apr猫s le 30 juin 2025. La soci茅t茅 dispose d'environ 3.42M de warrants en circulation et a des engagements d'achat ouverts d'environ $8.3M.
Ensysce Biosciences ist ein Biotech-Unternehmen in der klinischen Entwicklungsphase, das sich auf TAAP- und MPAR-Technologien konzentriert; PF614 befindet sich in Phase 3 und PF614-MPAR in Phase 1b. Das Unternehmen meldete am 30. Juni 2025 $2.21 million in cash (von $3.50M), Gesamtverm枚gen von $5.57 million und Gesamtverbindlichkeiten von $2.51 million. F眉r die sechs Monate zum 30. Juni 2025 betrug der Nettoverlust $3.68 million gegen眉ber $5.08M im Vorjahr; die Einnahmen aus Bundeszusch眉ssen beliefen sich bisher auf $2.69 million und die verbleibende NIH-MPAR-Zuschussfinanzierung wurde zum 30. Juni 2025 mit $9.4 million angegeben. Das Management weist erhebliche Zweifel an der F盲higkeit des Unternehmens aus, als fortf眉hrendes Unternehmen fortzubestehen und erkl盲rt, dass die derzeitigen Barmittel bis ins dritte Quartal 2025 ausreichen. K眉rzliche Finanzierungsma脽nahmen erzielten Bruttoerl枚se von etwa $2.2M durch eine Warrant-Induzierung im April 2025 und etwa $1.1M durch ein im M盲rz 2025 registriertes Direktangebot, wobei zus盲tzlich $1.1M aus Warrant-Aus眉bungen nach dem 30. Juni 2025 eingeworben wurden. Das Unternehmen h盲lt etwa 3.42M ausstehende Warrants und hat offene Kaufverpflichtungen von rund $8.3M.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended:
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
File Number
(Exact name of registrant as specified in its charter)
(State
or other jurisdiction of |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) |
| (Registrant’s telephone number, including area code) |
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
Registrant
had
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or the negative of these terms or other similar expressions intended to identify statements about the future. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about:
| ● | our estimates regarding expenses, revenue, capital requirements and timing and availability of and the need for additional financing will almost certainly not match actual amounts and timing; | |
| ● | our ability to continue as a going concern for the next twelve months; | |
| ● | the risk that our lead product candidate PF614 and PF614-MPAR may not be successful in limiting or impeding abuse, overdose, or misuse or providing additional safety upon commercialization; | |
| ● | reliance by us on third-party contract research organizations, or CROs, for our research and development activities and clinical trials; | |
| ● | the need for substantial additional funding to complete the development and commercialization of our product candidates; | |
| ● | the risk that our clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties; | |
| ● | the risk that the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; | |
| ● | the risk that clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this Quarterly Report on Form 10-Q; | |
| ● | the risk that we will be unable to successfully market or gain market acceptance of our product candidates; | |
| ● | the risk that our product candidates may not be beneficial to patients or successfully commercialized; |
| i |
| ● | the risk that we have overestimated the size of the target market, patients’ willingness to try new therapies, and the willingness of physicians to prescribe these therapies; | |
| ● | effects of competition; |
| ● | the risk that third parties on which we depend for laboratory, clinical development, manufacturing, and other critical services will fail to perform satisfactorily; | |
| ● | the risk that our business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics | |
| ● | the risk that we will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; |
| ● | the loss of key members of our management team; | |
| ● | changes in our regulatory environment; | |
| ● | the ability to attract and retain key scientific, medical, commercial, or management personnel; | |
| ● | changes in our industry; | |
| ● | our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting; | |
| ● | the risk that our common stock will be delisted from Nasdaq; | |
| ● | the risk that we may not be able to maintain compliance with applicable listing standards of Nasdaq; | |
| ● | potential litigation associated with the Business Combination Transactions; | |
| ● | other factors disclosed in this Quarterly Report on Form 10-Q; and | |
| ● | other factors beyond our control. |
The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on Ensysce’s current expectations and beliefs concerning future developments and their potential effects on Ensysce. There can be no assurance that future developments affecting Ensysce will be those that Ensysce has anticipated. These forward-looking statements involve risks, uncertainties (some of which are beyond Ensysce’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Moreover, the occurrence of the events described in the “Risk Factors” in our Annual Report on Form 10-K may adversely affect Ensysce. Ensysce will not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
| ii |
GLOSSARY
| Definitions: | ||
| 2021 Notes | The senior secured convertible promissory notes in the aggregate original principal amount of $15.9 million, sold in two closings on September 24, 2021, and November 5, 2021, respectively, pursuant to the Securities Purchase Agreement entered into on September 24, 2021 | |
| 2021 Omnibus Incentive Plan | Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan (“Plan”) | |
| 2022 Notes | The senior secured convertible promissory notes in the aggregate original principal amount of $8.5 million, sold in two closings on June 30, 2022, and August 8, 2022, respectively, pursuant to the Securities Purchase Agreement entered into on June 30, 2022 | |
| 2023 Notes | The senior secured convertible promissory notes in the aggregate original principal amount of $1.8 million, sold in two closings on October 25, 2023, and November 28, 2023, respectively, pursuant to the Securities Purchase Agreement entered into on October 23, 2023 | |
| 2023 May Offering | The Company’s May 2023 registered direct offering of common stock (including pre-funded warrants in lieu thereof) for aggregate consideration of $7.0 million | |
| 2024 February Warrant Inducement | The Company’s February 2024 transaction including the cash exercise of certain existing warrants at a reduced price and the issuance of new warrants | |
| 2024 August Warrant Inducement | The Company’s August 2024 transaction including the cash exercise of certain existing warrants at a reduced price and the issuance of new warrants | |
| August Inducement Letter | Inducement offer letter entered into with certain holders of existing warrants to purchase 480,234 shares of the Company’s common stock (issued in February of 2024) to reduce the exercise price from $15.90 per share to $7.05 per share. The Company also agreed to amend certain existing warrants to purchase up to an aggregate of 133,334 shares of common stock that were previously issued in November 2023 and had an exercise price of $23.51 per share such that the amended warrants have a reduced exercise price of $7.05 per share. | |
| 2025 Registered Direct Offering | A definitive Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell in a registered direct offering | |
| 2025 March Warrant Offering | An agreement by the Company to issue and sell unregistered warrants of Common Stock, Series A-5, and Series A-6 warrants to purchase shares of Common Stock | |
2025 April Warrant Inducement
|
The Company’s April 2025 Inducement offer letter entered into with certain holders of existing warrants to purchase 630,376 shares of the Company’s common stock (issued in March of 2025) and the issuance of new warrants exercisable for an aggregate of up to 1,260,752 shares of common stock with an exercise price of $1.90 per share. | |
| CMOs | Contract manufacturing organizations | |
| Company | Ensysce Biosciences, Inc. and its consolidated subsidiaries | |
| Covistat | A subsidiary renamed EBIR, Inc. | |
| CROs | Contract research organizations | |
| EB | Ensysce Biosciences, Inc. prior to its merger with Signature Acquisition Corp. pursuant to the EB-ST Agreement. | |
| EBIR | Previously known as Covistat, Inc., EBIR, Inc. is a clinical stage pharmaceutical company that is developing a compound utilized in the Company’s overdose protection program for the treatment of COVID-19 and 79.2%-owned subsidiary of the Company | |
| EB-ST Agreement | Agreement and Plan of Merger, dated as of December 28, 2015, by and among Signature, SAQ, and EB | |
| Ensysce | Ensysce Biosciences, Inc. | |
| Exchange Act | Securities Exchange Act of 1934, as amended |
| iii |
| Definitions: | ||
| FDA | United States Food and Drug Administration | |
| Former Ensysce | Ensysce Biosciences, Inc., a Delaware corporation, prior to the consummation of the merger with and into Merger Sub | |
| GAAP | Generally Accepted Accounting Principles in the United States of America | |
| JOBS Act | Jumpstart Our Business Startups Act of 2012 | |
| LACQ | Leisure Acquisition Corp., a Delaware Corporation | |
| Merger | The merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and a wholly owned subsidiary of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger. | |
| Merger Sub | EB Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of LACQ prior to the consummation of the Merger | |
| MPAR Grant | Research and development grant related to the development of its MPAR® overdose prevention technology awarded to the Company by NIH through NIDA in September 2018 | |
| Nasdaq | The Nasdaq Stock Market LLC | |
| NIDA | National Institute of Drug Abuse | |
| NIH | National Institutes of Health | |
| OUD Grant | Research and development grant related to the development of its TAAP/MPAR® abuse deterrent technology for Opioid Use Disorder awarded to the Company by NIH/NIDA in September 2019 | |
| Registered Direct Offering | August 2024 registered direct offering of common stock (236,880 shares), private placement warrants (to purchase up to 473,760 shares) and the cash exercise of certain existing warrants (480,234 warrant shares) at a reduced price and the issuance of new warrants (to purchase up to 1,440,701 shares). | |
| SAQ | Signature Acquisition Corp., a wholly-owned subsidiary of Signature | |
| SEC | U.S. Securities and Exchange Commission | |
| Securities Act | Securities Act of 1933, as amended | |
| Securities Purchase Agreement | The Securities Purchase Agreement, in September 2021, June 2022, October 2023, August 2024, or March 2025, as the context dictates, by and between Ensysce and the institutional investors party thereto | |
| Signature | Signature Therapeutics Inc. | |
| SPA | The Securities Purchase Agreement, in September 2021, June 2022, October 2023, August 2024, or March 2025, as the context dictates, by and between Ensysce and the institutional investors party thereto | |
| TAAP | Trypsin Activated Abuse Protection |
| iv |
Table of Contents
| Page | ||
| Forward-Looking Statements | i | |
| Glossary | iii | |
| PART I. | FINANCIAL INFORMATION | 1 |
| Item 1. | Financial Statements (Unaudited) | 1 |
| Consolidated Balance Sheets | 1 | |
| Consolidated Statements of Operations | 2 | |
| Consolidated Statements of Changes in Stockholders’ Equity | 3 | |
| Consolidated Statements of Cash Flows | 4 | |
| Notes to Consolidated Financial Statements (Unaudited) | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 29 |
| Item 4. | Controls and Procedures | 29 |
| PART II. | OTHER INFORMATION | 30 |
| Item 1. | Legal Proceedings | 30 |
| Item 1A. | Risk Factors | 30 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 30 |
| Item 3. | Defaults Upon Senior Securities | 30 |
| Item 4. | Mine Safety Disclosures | 30 |
| Item 5. | Other Information | 30 |
| Item 6. | Exhibits | 30 |
| Signatures | 31 |
| v |
Ensysce Biosciences, Inc.
Consolidated Balance Sheets
| June 30, 2025 (Unaudited) | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Unbilled receivable | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses and other liabilities | ||||||||
| Notes payable and accrued interest | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities: | ||||||||
| Other long-term liabilities | ||||||||
| Total long-term liabilities | ||||||||
| Total liabilities | $ | $ | ||||||
| Commitments and contingencies (Note 7) | - | - | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $ | $ | - | $ | - | ||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Ensysce Biosciences, Inc. stockholders’ equity | ||||||||
| Noncontrolling interests in stockholders’ deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| 1 |
Ensysce Biosciences, Inc.
Consolidated Statements of Operations
(Unaudited)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Federal grants | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Change in fair value of liability classified warrants | ( | ) | ||||||||||||||
| Interest expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income and expense, net | ( | ) | ||||||||||||||
| Total other income (expense), net | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss attributable to noncontrolling interests | ( | ) | - | ( | ) | ( | ) | |||||||||
| Deemed dividend related to warrants down round provision | - | - | - | |||||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per basic and diluted share: | ||||||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding, basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| 2 |
Ensysce Biosciences, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
| Number of Shares | Amount | Paid-In Capital | Accumulated Deficit | Noncontrolling interests | Total | |||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||||||
| Common Stock | Additional | |||||||||||||||||||||||
| Number of Shares | Amount | Paid-In Capital | Accumulated Deficit | Noncontrolling interests | Total | |||||||||||||||||||
| Balance on March 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Issuance of common stock upon inducement of warrants | ( | ) | - | - | - | |||||||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Reversed stock-split rounding adjustment | ( | ) | - | - | - | - | - | |||||||||||||||||
| Net loss | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||
| Balance on June 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Balance on March 31, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Issuance of common stock upon exercise of warrants | - | - | ||||||||||||||||||||||
| Issuance of common stock upon warrant inducement, net of issuance cost | - | - | ||||||||||||||||||||||
| Transaction costs associated with warrant inducement | - | - | ( | ) | - | - | ( | ) | ||||||||||||||||
| Consultant settlement | - | - | ||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | ( | ) | |||||||||||||||
| Balance on June 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Balance on December 31, 2023 | $ | $ | ( | ) | ( | ) | ( | ) | ||||||||||||||||
| Settlement of restricted stock units | — | — | — | — | — | |||||||||||||||||||
| Conversion of convertible notes | — | — | ||||||||||||||||||||||
| Issuance of common stock upon exercise of warrants | — | — | ||||||||||||||||||||||
| Issuance of common stock upon warrant inducement, net of issuance cost | — | |||||||||||||||||||||||
| Transaction costs associated with warrant inducement | — | — | ( | ) | — | — | ( | ) | ||||||||||||||||
| Stock-based compensation | — | — | — | — | ||||||||||||||||||||
| Reversed stock-split rounding adjustment | ( | ) | — | — | — | — | — | |||||||||||||||||
| Deemed dividend related to warrant down round provision | — | — | ( | ) | — | — | ||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||
| Balance on June 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Balance on December 31, 2024 | $ | $ | ( | ) | ( | ) | ||||||||||||||||||
| Balance | $ | $ | ( | ) | ( | ) | ||||||||||||||||||
| Public offering | — | — | ||||||||||||||||||||||
| Issuance of common stock upon exercise of warrants | — | — | ||||||||||||||||||||||
| Transaction costs associated with public offering | — | — | ( | ) | — | — | ( | ) | ||||||||||||||||
| Issuance of common stock upon warrant inducement, net of issuance cost | — | — | ||||||||||||||||||||||
| Transaction costs associated with warrant inducement | — | — | ( | ) | — | — | ( | ) | ||||||||||||||||
| Consultant compensation | — | — | ||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | ||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||
| Balance on June 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Balance | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| 3 |
Ensysce Biosciences, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
| 2025 | 2024 | |||||||
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Accrued interest | ||||||||
| Amortization of orginal issue discount and debt issuance costs | - | |||||||
| Change in fair value of liability classified warrants | ( | ) | ( | ) | ||||
| Consultant compensation | - | |||||||
| Stock-based compensation | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Unbilled receivable | ( | ) | ( | ) | ||||
| Prepaid expenses and other assets | ||||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses and other liabilities | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from public offerings | - | |||||||
| Proceeds from warrant exercises | ||||||||
| Proceeds from warrant inducement, net of issuance costs | ||||||||
| Transaction costs from public offerings | ( | ) | - | |||||
| Transaction costs associated with warrant inducements | ( | ) | ( | ) | ||||
| Repayment of convertible notes | - | ( | ) | |||||
| Repayment of financed insurance premiums | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Increase (decrease) in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents beginning of period | ||||||||
| Cash and cash equivalents end of period | $ | $ | ||||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Incremental fair value of February 2024 Warrant Inducement | $ | - | $ | |||||
| Incremental fair value of April 2025 Warrant Inducement | $ | $ | - | |||||
| Conversion of convertible notes into common stock | $ | - | $ | |||||
| Transaction costs from warrant inducement | $ | - | $ | |||||
| Transaction costs from public offerings | $ | $ | - | |||||
| Deemed dividend related to warrants down round provision | $ | - | $ | |||||
| Financed insurance premiums | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| 4 |
Ensysce Biosciences, Inc.
Notes to the Consolidated Financial Statements
(Unaudited)
NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES
Ensysce
Biosciences, Inc. (“Ensysce”), along with its
In
2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation
of a separate entity, EBIR, a Delaware corporation. Pursuant to the articles of incorporation, EBIR was authorized to issue
NOTE 2 - BASIS OF PRESENTATION
The consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.
Reverse Stock Split
In
December 2024, the Company completed a
All references in these consolidated financial statements to shares and per share amounts in all periods have been retrospectively restated to reflect the effects of both reverse splits noted above. The number of authorized shares and the par value of the shares did not change as a result of the reverse stock splits.
Going Concern
The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.
The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, would be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.
The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.
| 5 |
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates and Assumptions
Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.
Cash and Cash Equivalents
For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as
Segments
The
Company operates and manages its business as
Property and Equipment
Property
and equipment are fully depreciated, as such there is
Fair Value Measurement
ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.
The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:
| Level 1: | Quoted prices in active markets for identical assets or liabilities. |
| Level 2: | Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. | |
| Level 3: | Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. |
| 6 |
The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.
As of June 30, 2025, and December 31, 2024, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.
Warrants
The Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 9 for additional details of the warrants.
The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of June 30, 2025, and December 31, 2024.
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| June 30, 2025 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Liability classified warrants | $ | $ | - | $ | - | $ | ||||||||||
| Total | $ | $ | - | $ | - | $ | ||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| December 31, 2024 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Liability classified warrants | $ | $ | - | $ | - | $ | ||||||||||
| Total | $ | $ | - | $ | - | $ | ||||||||||
The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the year ended June 30, 2025 (no level 3 assets as of June 30, 2025):
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3
| Liability classified warrants | ||||
| Fair value, December 31, 2024 | $ | |||
| Change in fair value | ( | ) | ||
| Fair value, June 30, 2025 | $ | |||
Federal Grants
In
September 2018, the NIH through the NIDA awarded the Company a research and development MPAR Grant. The initial grant was extended several
times and cumulative funding under this grant of approximately $
| 7 |
In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for OUD Grant. The total approved budget was approximately $
The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.
The revenue recognized under the MPAR Grant and OUD Grant was as follows:
SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| MPAR | $ | $ | - | $ | $ | - | ||||||||||
| TAAP/OUD | - | - | ||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.
Research and Development Costs
The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based Compensation
The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.
The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in research and development and general and administrative expenses in the consolidated statements of operations.
From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.
| 8 |
Income Taxes
Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Earnings (loss) per Share
The basic earnings (loss) per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period.
The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below):
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Stock options | ||||||||||||||||
| Warrants | ||||||||||||||||
| Convertible Notes | ||||||||||||||||
| Consultant Shares | - | - | ||||||||||||||
| Total | ||||||||||||||||
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement on its related disclosures.
In November 2024, the FASB issued ASU 2024-04, “Debt – Debt with Conversion and other Options (Subtopic 470-20) “, which set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt— Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
| 9 |
NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consisted of the following:
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
| June 30, 2025 | December 31, 2024 | |||||||
| Prepaid research and development | $ | $ | ||||||
| Prepaid insurance | ||||||||
| Other prepaid expenses | ||||||||
| Other current assets | ||||||||
| Total prepaid expenses and other current assets | $ | $ | ||||||
NOTE 5 – OTHER ASSETS
SCHEDULE OF OTHER ASSETS
| June 30, 2025 | December 31, 2024 | |||||||
| Prepaid insurance | $ | $ | ||||||
| Deposits | ||||||||
| Total other assets | $ | $ | ||||||
NOTE 6 – ACCRUED EXPENSES AND OTHER LIABILITIES
Accrued expenses and other liabilities consisted of the following:
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES
| June 30, 2025 | December 31, 2024 | |||||||
| Accrued research and development | $ | $ | ||||||
| Accrued consultant compensation | - | |||||||
| Accrued professional fees | ||||||||
| Other accrued liabilities | ||||||||
| Total accrued expenses and other liabilities | $ | $ | ||||||
NOTE 7 - COMMITMENTS AND CONTINGENCIES
Purchase Commitments
As
of June 30, 2025, the Company’s commitments included an estimated $
Litigation
As of June 30, 2025, and December 31, 2024, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.
| 10 |
Consultant Dispute
In
April 2025, the Company entered into an agreement with a former independent contractor to resolve a dispute over payment. The Company
denied the allegations but agreed to settle the matter. In connection with the settlement agreement, the Company issued
Galephar Agreement
In January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto Rico specialty drug manufacturer (“Galephar”), to support the development, manufacture, packaging and testing of the Company’s PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch.
Upon
signing, the Company committed to issue
Lease
The
Company’s current lease agreement (as amended) has a term that extends through October 31, 2025, with no option to renew. As of
June 30, 2025, the future lease payments totaled $
NOTE 8 - NOTES PAYABLE
The following table provides a summary of the Company’s outstanding debt as of June 30, 2025:
SCHEDULE OF DEBT
| Principal balance | Accrued interest | Net debt balance | ||||||||||
| 2023 Notes | $ | $ | $ | |||||||||
| Financed insurance | - | |||||||||||
| Total | $ | $ | $ | |||||||||
The following table provides a summary of the Company’s outstanding debt as of December 31, 2024:
| Principal balance | Accrued interest | Net debt balance | ||||||||||
| 2023 Notes | $ | $ | $ | |||||||||
| Financed insurance | - | |||||||||||
| Total | $ | $ | $ | |||||||||
| 11 |
Interest expense
The
interest expense recognized for financed insurance was $
2023 Notes
In
October 2023, the Company entered into a Securities Purchase Agreeement (“SPA”) for an aggregate financing of $
The
Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative
fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of
the balance sheet. The amortization of the original debt discount (approximately $
The
warrants have an exercise price of $
During
2024, the Company converted
Financed Insurance Premiums
In
June 2025, the Company renewed and financed its directors’ and officers’ liability insurance in the amount of $
NOTE 9 - STOCKHOLDERS’ EQUITY
The
Company’s current Certificate of Incorporation authorizes
2025 April Warrant Inducement
In
April 2025, the Company entered into an Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
to purchase up to an aggregate of
| 12 |
In
consideration for the immediate exercise of the warrants for cash and the payment of an additional $
The
Company utilized a placement agent for the 2025 April Warrant Inducement and incurred approximately $
2025 Registered Direct Offering and 2025 March Warrant Offering
In
March 2025, the Company entered into a definitive SPA with certain institutional investors, pursuant to which the Company agreed to issue
and sell in a registered direct offering, (i) an aggregate of
In
a concurrent private placement, pursuant to the terms of the SPA, the Company also agreed to issue and sell unregistered warrants to
purchase up to
2024 Registered Direct Offering and 2024 August Warrant Inducement
In
August 2024, the Company entered into a definitive SPA with certain institutional investors, pursuant to which the Company agreed to
issue and sell in a registered direct offering, (i) an aggregate of
The
Company also entered into the August Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
to purchase up to an aggregate of
In
a concurrent private placement, pursuant to the terms of the August Inducement Letter and SPA, the Company utilized an exclusive placement
agent for the 2024 Registered Direct Offering and 2024 August Warrant Inducement and incurred approximately $
2024 February Warrant Inducement
In
February 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of
| 13 |
In connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes’ SPA it had entered into as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note 8 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant inducement.
The
Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $
Warrants
The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2025:
SCHEDULE OF OUTSTANDING WARRANT
| Reference | Shares Underlying Outstanding Warrants | Exercise Price | Description | Classification | ||||||||
| (a) | $ | Equity | ||||||||||
| (b) | $ | Equity | ||||||||||
| (c) | $ | Equity | ||||||||||
| (d) | $ | Equity | ||||||||||
| (e) | $ | Equity | ||||||||||
| (f) | $ | Equity & Liability | ||||||||||
(a) |
|
| (b) | |
| (c) | |
| (d) | |
| (e) |
| 14 |
| (f) |
NOTE 10 - STOCK-BASED COMPENSATION
In
connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2025, the Company’s
Board approved an annual increase of
The
Company recognized within general and administrative expense stock-based compensation expense of $
Option Activity
During
the six months ended June 30, 2025, the Company granted stock options to purchase an aggregate of
The following table summarizes the Company’s stock option activity during the six months ended June 30, 2025:
SCHEDULE OF STOCK OPTION ACTIVITY
| Weighted average | ||||||||||||||||
| Options | Exercise price | Remaining contractual life | Intrinsic value | |||||||||||||
| Outstanding at December 31, 2024 | $ | $ | - | |||||||||||||
| Granted | - | |||||||||||||||
| Exercised | - | - | - | - | ||||||||||||
| Expired / Forfeited | - | - | - | - | ||||||||||||
| Outstanding at June 30, 2025 | - | |||||||||||||||
| Exercisable at June 30, 2025 | - | |||||||||||||||
| Vested and expected to vest | - | |||||||||||||||
Option Valuation
The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows:
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS
| June 30, 2025 | ||||
| Exercise price | $ | |||
| Expected stock price volatility | ||||
| Expected term (years) | ||||
| Risk-free interest rate | | |||
| Expected dividend yield | % | |||
| ● | Expected stock-price volatility. The expected volatility is derived from the historical volatilities of comparable publicly traded companies within the Company’s industry that the Company considers comparable to the Company’s business over a period approximately equal to the expected term. |
| 15 |
| ● | Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. | |
| ● | Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term. | |
| ● | Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock. |
The
weighted-average grant date fair value of options granted during the six months ended June 30, 2025 was $
As
of June 30, 2025, the Company had an aggregate of $
Shares Reserved for Future Issuance
The following shares of common stock are reserved for future issuance:
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE
| June 30, 2025 | ||||
| Awards outstanding under the Plan | ||||
| Awards available for future grant under the Plan | ||||
| Warrants outstanding | ||||
| Shares for consultant compensation agreement outside the Plan | ||||
| Total shares of common stock reserved for future issuance | ||||
NOTE 11 - RELATED PARTIES
As
of June 30, 2025, the Company held a $
NOTE 12 - SUBSEQUENT EVENTS
The
Company has issued
| 16 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and notes thereto included elsewhere in this report. In addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section within Part II-Other Information - titled “Item 1A. Risk Factors.”
References in the following discussion to “we”, “us”, “our” and the “Company” refer to Ensysce Biosciences, Inc. and its consolidated subsidiaries following the Closing of the Business Combination. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.
Overview
Ensysce is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our lead product candidate, PF614, is an extended release TAAP prodrug of oxycodone. TAAP modification of prescription drugs removed the ability to crush, chew or manipulate and inject to achieve the effect of the medication more quickly than by swallowing. MPAR® adds a layer of overdose protection to each TAAP product.
Since our inception in 2003, we devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our product candidates. We do not have any products approved for sale and we have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product.
Our lead product candidate, PF614, is in Phase 3 clinical development, PF614-MPAR is in Phase 1b clinical development and nafamostat has completed Phase 1 clinical development. Our other product candidates and our research initiatives are in preclinical or earlier stages of development. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. We have not yet successfully completed any pivotal clinical trials, nor have we obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.
We have incurred significant operating losses since inception and we expect to continue to incur net losses for the foreseeable future. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing development activities, particularly if and as we:
| ● | continue preclinical studies and continues existing and initiates new clinical trials for PF614, PF614-MPAR and nafamostat, our lead product candidates being tested for chronic pain and infectious disease; | |
| ● | advance the development of our product candidate pipeline of other product candidates, including through business development efforts to invest in or in-license other technologies or product candidates; | |
| ● | maintain, expand and protect our intellectual property portfolio; | |
| ● | hire additional clinical, quality control, medical, scientific and other technical personnel to support our clinical operations; | |
| ● | seek regulatory approval for any product candidates that successfully complete clinical trials; | |
| ● | undertake any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval; | |
| ● | expand our infrastructure and facilities to accommodate our growing employee base; and | |
| ● | add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our transition to operating as a public company. |
| 17 |
We have incurred and expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses. We may never become profitable.
We require substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of private and public equity offerings, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, existing ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our equity holders.
Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, issuing additional equity, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations or other strategic transactions with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
We have generated limited revenues and have incurred significant operating losses since our inception and expect to continue to incur operating losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern. Our future viability is dependent on our ability to raise additional capital to finance our operations. Without raising additional capital through a future offering, we believe that current cash on hand is sufficient to fund operations into the third quarter of 2025. We based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “— Liquidity and Capital Resources.” Our future viability beyond the twelve months is dependent on our ability to raise additional capital to finance our operations.
We expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding in the future.
2025 April Warrant Inducement
In April 2025, we entered into an Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants to purchase up to an aggregate of 630,736 share of our common stock, par value $0.0001 per share. The warrants were issued in March 2025 with an exercise price of $3.24 share. The shares of common stock issuable upon exercise of such outstanding warrants are registered pursuant to an effective register statement on Form S-3.
| 18 |
In consideration for the immediate exercise of the warrants for cash and the payment of an additional $0.125 per new unregistered warrant (an additional $157,594 included in our gross proceeds), pursuant to the Inducement Agreement, we agreed to issue and sell unregistered warrants to purchase shares of common stock. The new warrants (the “Common Warrants”) are exercisable for an aggregate of up to 1,260,752 shares of common stock. The Common Warrants have an exercise price of $1.90 per share and are immediately exercisable for shares of common stock. One half of the Common Warrants will expire after eighteen (18) months and the other half will expire after five (5) years. Our gross proceeds from the exercise of the warrants and payment for Common Warrants was approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses.
We utilized a placement agent for the 2025 April Warrant Inducement and incurred approximately $0.3 million in legal fees and other closing costs. Additionally, we issued to the placement agent as compensation unregistered warrants to purchase up to 44,126 shares of common stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement agent warrants expire on April 24, 2030, and have an exercise price of $4.05 per share of common stock. The closing of the offering occurred on April 24, 2025.
2025 Registered Direct Offering and 2025 March Warrant Offering
In March 2025, we entered into a definitive SPA with certain institutional investors, pursuant to which we agreed to issue and sell in a registered direct offering, (i) an aggregate of 239,594 shares of common stock, par value $0.0001 per share at an offering price of $3.49 per share, (ii) pre-funded warrants to purchase up to 75,594 shares of common stock, at a price per pre-funded warrant equal to $3.4899, the price per share less $0.0001, for gross proceeds of approximately $1.1 million before the deduction of placement agent fees and offering expenses. The pre-funded warrants were fully exercised as of March 31, 2025, and the related common shares were issued in April 2025.
In a concurrent private placement, pursuant to the terms of the SPA, we also agreed to issue and sell unregistered warrants to purchase up to 315,188 shares of Common Stock (the “Series A-5 Warrants”), and Series A-6 warrants to purchase up to 315,188 shares of Common Stock (the “Series A-6 Warrants”), to purchase up to an aggregate 630,376 shares of Common Stock. The warrants have an exercise price of $3.24 per share and are exercisable immediately. The Series A-5 Warrants will expire eighteen (18) months after issuance and the Series A-6 Warrants will expire five (5) years after issuance. The warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.
We agreed to pay the placement agent a cash fee equal to 7% of the aggregate gross proceeds of the offerings or $77,000. We also agreed to pay the placement agent $65,950 for expenses. We also issued to the placement agent warrants to purchase up to 22,063 shares of common stock. These warrants have an exercise price equal to $4.3625 per share and are exercisable for five years.
2024 Registered Direct Offering and 2024 August Warrant Inducement
In August 2024, we entered into a definitive SPA with certain institutional investors, pursuant to which we agreed to issue and sell in a registered direct offering, (i) an aggregate of 166,054 shares of our common stock, par value $0.0001 per share at an offering price of $7.05 per share, (ii) pre-funded warrants to purchase up to 70,827 shares of Common Stock, at a price per pre-funded warrant equal to $7.0485, the price per share less $0.0015, for gross proceeds of approximately $1.7 million before the deduction of placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full.
We also entered into an inducement agreement with certain warrant holders for the exercise of certain outstanding warrants to purchase up to an aggregate of 480,234 shares of our common stock originally issued in February 2024, having an exercise price of $15.90 per share, at a reduced exercise price of $7.05 per share, for gross proceeds of approximately $3.4 million before the deduction of placement agent fees and offering expenses. We also agreed to amend certain existing warrants to purchase up to an aggregate of 133,334 shares of common stock that were previously issued in November 2023 and have an exercise price of $23.5125 per share such that the amended warrants will have a reduced exercise price of $7.05 per share effective upon the closing of the offering and will be exercisable from the date on which stockholder approval is received with respect to the issuance of the shares of common stock issuable upon exercise of such warrants.
| 19 |
In a concurrent private placement, pursuant to the terms of the inducement agreement and SPA, we also agreed to issue and sell unregistered warrants to purchase up to 1,863,706 shares of common stock. The warrants have an exercise price of $7.05 per share and are exercisable from the date on which stockholder approval is received with respect to the issuance of the shares of common stock issuable upon exercise of the warrants. One half of the warrants will expire eighteen months after they are exercisable and the other half will expire five years after they are exercisable. The warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.
We agreed to pay the placement agent a cash fee equal to 7% of the aggregate gross proceeds of the offerings or $354,000. We also agreed to pay the placement agent $100,950 for expenses. We also issued to the placement agent warrants to purchase up to 50,200 shares of common stock. These warrants have an exercise price equal to $8.8125 per share and are exercisable for five years from the commencement of sales in the Offerings.
2024 February Warrant Inducement
In February 2024, we entered into an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 240,120 shares of our common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of 240,120 shares of Common Stock at a reduced exercise price of $19.65 per share in consideration of our agreement to issue new unregistered Series A Warrants to purchase up to 240,120 shares of Common Stock and new unregistered Series B Warrants to purchase up to 240,120 shares of Common Stock. The Series A Warrants have an exercise price of $15.90 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an exercise price of $15.90 per share and will expire on May 12, 2028. The gross proceeds to us from the exercise of the warrants were approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses.
In connection with the execution of the Inducement Letter, we entered into a waiver related to the 2023 Notes’ SPA it had entered into as of October 23, 2023. The SPA contained restrictions on our ability to undertake certain transactions, which included entering into the Inducement Letter. The Waiver permitted us to enter into the Inducement Letter but required repayment of the remaining $0.5 million of investor held notes issued under the SPA with a premium of $0.5 million following closing of the inducement transaction.
We utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $0.3 million in legal fees and other closing costs. Additionally, we issued to the placement agent as compensation unregistered warrants to purchase up to 16,811 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement agent warrants expire on May 12, 2028, and have an exercise price of $24.5625 per share of Common Stock (equal to 125% of the reduced exercise price per Existing Warrant).
Components of Our Operating Results
Revenue
We have generated limited revenue since our inception and we do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts are successful and we commercialize our products, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, as well as upfront, milestone and royalty payments from such collaboration or license agreements, or a combination thereof.
We have received funding under federal grants from the NIH through NIDA. In September 2018 and August 2024, we were awarded a research and development MPAR Grant. In September 2019, we were awarded a second research and development OUD grant related to the development of our TAAP/MPAR® abuse deterrent technology. Grant funds are awarded annually through a Notice of Award which contains certain terms and conditions including, but not limited to, complying with the grant program legislation, regulation and policy requirements, complying with conditions on expenditures of funds with respect to other applicable statutory requirements such as the federal appropriations acts, periodic reporting requirements, and budget requirements.
| 20 |
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for research activities, including drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:
| ● | expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; | |
| ● | expenses incurred under agreements with CROs that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and CMOs that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs; | |
| ● | other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; | |
| ● | payments made in cash or equity securities under third-party licensing, acquisition and option agreements; | |
| ● | employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; | |
| ● | costs related to compliance with regulatory requirements; and | |
| ● | allocated facilities-related costs, depreciation and other expenses, which include rent and utilities. |
We recognize external development costs as incurred. Any advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. We estimate and accrue for the value of goods and services received from CROs and other third parties each reporting period based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs.
We do not track our research and development expenses on a program-by-program basis. Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and development as well as to manage our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by program and cannot state precisely the total costs incurred for each of our clinical and preclinical programs on a project-by-project basis.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will remain elevated as we continue our existing, and commence additional, planned clinical trials for PF614, PF614-MPAR® and nafamostat, as well as conduct other preclinical and clinical development, including submitting regulatory filings for our other product candidates, subject to our ability to obtain financing. We also expect our related personnel costs to increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, to remain elevated. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.
| 21 |
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates are highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:
| ● | the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities; | |
| ● | establishing an appropriate safety and efficacy profile with investigational new drug (“IND”) enabling studies; | |
| ● | successful patient enrollment in and the initiation and completion of clinical trials; | |
| ● | the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; | |
| ● | the extent of any required post-marketing approval commitments to applicable regulatory authorities; | |
| ● | establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; | |
| ● | development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; | |
| ● | obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; | |
| ● | significant and changing government regulation; | |
| ● | launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and | |
| ● | maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. |
Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of employee-related expenses, including salaries and related benefits, travel and stock-based compensation for personnel in executive, business development, finance, human resources, legal, information technology, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expense general and administrative costs as incurred.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the continued development of our product candidates, subject to our ability to obtain financing. We also anticipate that we will continue to incur significant accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.
| 22 |
Other Income (Expense)
Change in fair value of liability classified warrants
We use a Black-Scholes option pricing model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized through earnings for each reporting period.
Interest Expense
Interest expense consists of interest accrued on our financed directors’ and officers’ insurance, and interest from the 2023 Notes based on the stated interest rate. In addition, the 2023 Notes reflects amortization of the debt discount from the original issuance and a discount associated with the warrant issuances and amortization of the associated debt issuance costs that are all recorded as interest expense.
Provision for Income Taxes
We have not recorded any significant amounts related to income tax expense, we have not recognized any reserves related to uncertain tax positions, nor have we recorded any income tax benefits for the majority of our net losses we have incurred to date or for our research and development tax credits.
We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or our tax returns. Deferred tax assets and liabilities are determined based on difference between the financial statement carrying amounts and tax bases of existing assets and liabilities and for loss and credit carryforwards, which are measured using the enacted tax rates and laws in effect in the years in which the differences are expected to reverse. The realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2025, and December 31, 2024, we continue to maintain a full valuation allowance against all of our deferred tax assets based on our evaluation of all available evidence.
Beginning in 2022, the Tax Cuts and JOBS Act, or the Tax Act, eliminated the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Internal Revenue Code Section 174. This has not impacted our effective tax rate or our cash tax payable in 2024; however, if the requirement to capitalize Section 174 expenditures is not modified, it may also impact our effective tax rate and our cash tax liability in future years.
We file income tax returns in the United States federal tax jurisdiction and state jurisdictions and may become subject to income tax audit and adjustments by related tax authorities. Our tax return period for United States federal income taxes for the tax years since 2021 remain open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions. We record reserves for potential tax payments to various tax authorities related to uncertain tax positions, if any. The nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial. These reserves are based on a determination of whether and how much a tax benefit taken by us in our tax filings or whether our position is more likely than not to be realized following the resolution of any potential contingencies related to the tax benefit. We develop our assessment of uncertain tax positions, and the associated cumulative probabilities, using internal expertise and assistance from third-party experts. As additional information becomes available, estimates are revised and refined. Differences between estimates and final settlement may occur resulting in additional tax expense. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of our provision for income taxes. To date, no amounts are being presented as an uncertain tax position.
| 23 |
The following table summarizes our results of operations for the three months ended June 30, 2025 and 2024
Results of Operations
Comparison of the Three Months Ended June 30, 2025 and 2024:
| Three Months Ended June 30, | ||||||||||||
| 2025 | 2024 | Change | ||||||||||
| Federal grants | $ | 1,371,438 | $ | 181,797 | $ | 1,189,641 | ||||||
| Operating expenses: | ||||||||||||
| Research and development | 1,923,430 | 947,229 | 976,201 | |||||||||
| General and administrative | 1,198,523 | 1,190,010 | 8,513 | |||||||||
| Total operating expenses | 3,121,953 | 2,137,239 | 984,714 | |||||||||
| Loss from operations | (1,750,515 | ) | (1,955,442 | ) | 204,927 | |||||||
| Other income (expense): | ||||||||||||
| Change in fair value of liability classified warrants | (853 | ) | 7,818 | (8,671 | ) | |||||||
| Interest expense | (3,160 | ) | (27,563 | ) | 24,403 | |||||||
| Other income and expense, net | 21,011 | 7,394 | 13,617 | |||||||||
| Total other income (expenses), net | 16,998 | (12,351 | ) | 29,349 | ||||||||
| Net loss | (1,733,517 | ) | (1,967,793 | ) | 234,276 | |||||||
| Net loss attributable to noncontrolling interests | (166 | ) | - | (166 | ) | |||||||
| Deemed dividend related to warrants down round provision | - | - | - | |||||||||
| Net loss attributable to common stockholders | $ | (1,733,351 | ) | $ | (1,967,793 | ) | $ | 234,442 | ||||
Federal Grants
Revenue from federal grants totaled $1.4 million for the three months ended June 30, 2025, compared to $0.2 million for the three months ended June 30, 2024, respectively. The $1.2 million difference is due to the timing of research activities eligible for funding, with increased activities in 2025 under the MPAR grant which began in September 2024. The 2024 period included limited funding under the OUD grant with research activity constrained until the selection of a lead product candidate in June 2024.
Research and Development Expenses
Research and development expenses were $1.9 million for the three months ended June 30, 2025, compared to $0.9 million for the three months ended June 30, 2024, representing an increase of $1.0 million. The increase was primarily the result of external research and development costs related to increased clinical and pre-clinical activity for PF614-MPAR in the 2025 period. We expect future research and development expenses to increase once we begin the Phase 3 clinical trial for PF614, with such timing dependent upon our ability to raise capital sufficient to fund these expenses.
General and Administrative Expenses
General and administrative expenses were $1.2 million for the three months ended June 30, 2025, and the three months ended June 30, 2024. We expect future general and administrative expenses to approximate current levels.
Other Income and Expense
Other income and expense for the three months ended June 30, 2025, consisted primarily of interest income from cash and cash equivalents. The comparative period for 2024 consisted primarily of interest expense associated with the amortization of the original issue discount and the debt issuance costs for the 2023 Notes.
| 24 |
Results of Operations
Comparison of the six months ended June 30, 2025 and 2024:
| Six Months Ended June 30, | ||||||||||||
| 2025 | 2024 | Change | ||||||||||
| Federal grants | $ | 2,691,210 | $ | 487,519 | $ | 2,203,691 | ||||||
| Operating expenses: | ||||||||||||
| Research and development | 3,808,957 | 1,726,133 | 2,082,824 | |||||||||
| General and administrative | 2,600,279 | 2,559,791 | 40,488 | |||||||||
| Total operating expenses | 6,409,236 | 4,285,924 | 2,123,312 | |||||||||
| Loss from operations | (3,718,026 | ) | (3,798,405 | ) | 80,379 | |||||||
| Other income (expense): | ||||||||||||
| Change in fair value of liability classified warrants | 9,063 | 16,773 | (7,710 | ) | ||||||||
| Interest expense | (7,017 | ) | (1,275,628 | ) | 1,268,611 | |||||||
| Other income and expense, net | 36,890 | (27,096 | ) | 63,986 | ||||||||
| Total other income (expenses), net | 38,936 | (1,285,951 | ) | 1,324,887 | ||||||||
| Net loss | (3,679,090 | ) | (5,084,356 | ) | 1,405,266 | |||||||
| Net loss attributable to noncontrolling interests | (166 | ) | (74 | ) | (92 | ) | ||||||
| Deemed dividend related to warrants down round provision | — | 290 | (290 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (3,678,924 | ) | $ | (5,084,572 | ) | $ | 1,405,648 | ||||
Federal grant funding
Funding from federal grants for the six months ended June 30, 2025 and 2024 totaled $2.7 million and $0.5 million, respectively. The increase of approximately $2.2 million is due to the timing of research activities eligible for funding, as funding under the initial MPAR grant was completed in December 2023 and funding under a subsequent MPAR grant began in September 2024.
Research and development expenses
Research and development expenses for the six months ended June 30, 2025, and 2024 were $3.8 million and $1.7 million, respectively, representing a increase of $2.1 million. The increase was primarily the result of external research and development costs related to increased clinical and pre-clinical programs for PF614 and PF614-MPAR. We expect future research and development expenses to increase once we begin the Phase 3 clinical trial for PF614, with such timing dependent upon our ability to raise capital sufficient to fund these expenses.
General and administrative expenses
General and administrative expenses for the six months ended June 30, 2025, and 2024 were $2.6 million for each period. We expect future general and administrative expenses to approximate current levels.
Other income and expense
Other income and expense for the six months ended June 30, 2025, consisted primarily of interest income from cash and cash equivalents. Other income and expense for the six months ended June 30, 2024, consisted primarily of interest expense associated with the amortization of the original issue discount and the debt issuance costs associated with the 2023 Notes.
| 25 |
Liquidity and Capital Resources
Sources of Liquidity and Capital
As of June 30, 2025, we had $2.2 million of cash and cash equivalents. Since inception, we have generated limited revenues and have incurred significant operating losses and negative cash flows from our operations, and we anticipate that we will continue to incur losses for at least the foreseeable future. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all.
We have funded our operations to date primarily with proceeds from the sale of common equity, exercise of warrants for common equity, funding under federal research grants and borrowings under convertible promissory notes. To fund future operations, we will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing research and development efforts and related general and administrative support. We anticipate that we will fund our operations through public or private equity or debt financings or other sources, such as potential collaboration agreements. We cannot make assurances that anticipated additional financing will be available to us on favorable terms, if at all.
The remaining funding under the MPAR federal research grant totaled $9.4 million at June 30, 2025, and is expected to be utilized by May 31, 2027. Pursuant to the terms and conditions, we are required to submit progress reports to NIDA on an annual basis and a final research performance progress report within 120 days of the performance period end date.
Going Concern
We have generated limited revenues and have incurred significant operating losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Without capital raised through financing transactions, existing cash resources are sufficient to allow us to fund current planned operations into the fourth quarter of 2025, which raises substantial doubt about our ability to continue as a going concern.
Cash Flows for the six months ended June 30, 2025, and 2024
The following table summarizes our cash flows for each of the periods presented:
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Net cash used in operating activities | $ | (4,414,280 | ) | $ | (5,718,294 | ) | ||
| Net cash provided by financing activities | 3,123,778 | 5,637,921 | ||||||
| Net decrease in cash and cash equivalents | $ | (1,290,502 | ) | $ | (80,373 | ) | ||
Operating Activities
During the six months ended June 30, 2025 and 2024, we used cash in operating activities of $4.4 million and $5.7 million, respectively. The decrease primarily resulted from greater cash inflows from grant funding in 2025 and a reduction in cash outlays for accounts payable in 2025.
Financing Activities
During the six months ended June 30, 2025, net cash provided by financing activities was $3.1 million, primarily consisting of net proceeds from warrant inducements, a public offering of common stock and warrant exercises. During the six months ended June 30, 2024, net cash provided by financing activities was $5.6 million, primarily consisting of net proceeds from a warrant inducement and warrant exercises, less repayment of convertible notes.
Funding Requirements
Our primary use of cash is to fund operating expenses, primarily related to our research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.
| 26 |
We expect our expenses, excluding non-cash expenses to recognize the fair value of warrants and convertible notes, to remain elevated in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we have incurred, and will continue to incur, additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:
| ● | advance preclinical development of our early-stage programs and clinical trials of our product candidates; | |
| ● | manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing; | |
| ● | seek regulatory approvals for any product candidates that successfully complete clinical trials; | |
| ● | establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own; | |
| ● | hire additional clinical, quality control and scientific personnel; | |
| ● | expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; | |
| ● | obtain, maintain, expand and protect our intellectual property portfolio; | |
| ● | manage the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and | |
| ● | manage the costs of operating as a public company. |
Commitments
Our commitments as of June 30, 2025, included an estimated $8.3 million related to open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule, and adjust requirements based on our business needs prior to the delivery of goods or the performance of services.
Working Capital
Because of the numerous risks and uncertainties associated with research, development and commercialization of biologic product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
| ● | the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials; | |
| ● | the costs, timing and outcome of regulatory review of our product candidates; | |
| ● | the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials; | |
| ● | the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; | |
| ● | the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch; |
| 27 |
| ● | the ability to receive additional non-dilutive funding, including grants from organizations and foundations; | |
| ● | the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval; | |
| ● | the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims; | |
| ● | our ability to establish and maintain collaborations on favorable terms, if at all; and | |
| ● | the extent to which we acquire or in-license other product candidates and technologies. |
Critical Accounting Policies and Significant Judgments and Estimates
Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 3 to our audited consolidated financial statements included in our 2024 Annual Report on Form 10-K, we believe that the following accounting policy is the most critical to the judgments and estimates used in the preparation of our consolidated financial statements.
Accrued Research and Development Expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual costs. Many of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and adjust if necessary. Examples of estimated accrued research and development expenses include fees paid to:
| ● | vendors, including research laboratories, in connection with preclinical development activities; | |
| ● | CROs and investigative sites in connection with preclinical studies and clinical trials; and | |
| ● | CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials. |
We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any period.
| 28 |
Off-Balance Sheet Arrangements
We do not have during the periods presented, and do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Smaller Reporting Company Status
We are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the prior June 30, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
We are exposed to market risk in the ordinary course of our business. These risks primarily relate to changes in interest rates and inflation.
Interest Rate Risk
Our cash and cash equivalents as of June 30, 2025, consisted of cash and a money market fund account. Because of the short-term nature of our money market fund, a sudden change in market interest rates would not be expected to have a material impact on our financial position or results of operations.
Inflation Risk
We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a–15(e) and 15d-15(e)) as of June 30, 2025. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2025. Management has concluded that our financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 29 |
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, we review the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation.
Item 1A. Risk Factors.
While we attempt to identify, manage and mitigate risks and uncertainties associated with our business to the extent practical, under the circumstances, some level of risk and uncertainty will always be present. Part I, Item 1A. Risk Factors of our 2024 Annual Report on Form 10-K includes a detailed discussion of our risk factors. Those risks and uncertainties have the potential to materially affect our financial condition and results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Information concerning the sale of unregistered securities in April 2025 was disclosed in a Current Report on Form 8-K filed on April 24, 2025.
On April 7, 2025, the Company entered into an agreement with a former independent contractor to resolve a dispute over payment, pursuant to which the Company issued 20,000 shares, bearing a restrictive legend, as compensation. The issuance involved no underwriters, underwriting discounts or commissions, or public offering and was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) as a transaction by an issuer not involving any public offering.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits.
The following exhibits are filed as part of this report:
Exhibit Number |
Description | |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Filed herewith.
| 30 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ENSYSCE BIOSCIENCES, INC. | |
| Date: August 13, 2025 | /s/ David Humphrey |
| David Humphrey | |
| Chief Financial Officer, Secretary and Treasurer |
| 31 |
Source:
FAQ
What is Ensysce's (ENSC) cash position at June 30, 2025?
How large was Ensysce's net loss for the six months ended June 30, 2025?
Does Ensysce disclose any going concern or runway information in the 10-Q?
What recent financings did Ensysce complete in 2025?
How much NIH/NIDA grant funding remains available to Ensysce?
How many warrants and shares are outstanding or reserved for issuance?
